Breaking News

Juno Therapeutics, Inc. v. Kite Pharma, Inc.

Pending petition
Docket No. Op. Below Argument Opinion Vote Author Term
21-1566 Fed. Cir. TBD TBD TBD TBD TBD

Issue: Whether the adequacy of the “written description of [an] invention” is measured by the statutory standard of “in such full, clear, concise, and exact terms as to enable any person skilled in the art to make and use the same” in 35 U.S.C. § 112(a), or by the Federal Circuit’s test that the “written description of the invention” must demonstrate the inventor’s “possession” of “the full scope of the claimed invention” including all “known and unknown” variations of each component.

DateProceedings and Orders (key to color coding)
Feb 25 2022Application (21A461) to extend the time to file a petition for a writ of certiorari from April 14, 2022 to June 13, 2022, submitted to The Chief Justice.
Mar 07 2022Application (21A461) granted by The Chief Justice extending the time to file until June 13, 2022.
Jun 13 2022Petition for a writ of certiorari filed. (Response due July 15, 2022)
Jun 28 2022Motion to extend the time to file a response from July 15, 2022 to August 24, 2022, submitted to The Clerk.
Jun 29 2022Motion to extend the time to file a response is granted and the time is extended to and including August 24, 2022.
Jul 15 2022Brief amicus curiae of City of Hope filed.
Jul 15 2022Brief amici curiae of Mark D. Janis and Timothy R. Holbrook filed.
Jul 15 2022Brief amicus curiae of REGENXBIO Inc. filed.
Jul 15 2022Brief amici curiae of Amgen Inc., et al. filed.
Jul 15 2022Brief amici curiae of St. Jude Children’s Research Hospital, Inc., et al. filed.